Cancer Survivor Takes Control of Insurance Nightmare

James Mannett’s cancer has cost around $600,000, including travel and other expenses, with about $100,000 of that coming from his own pocket. Mr. Mannett, who now lives in a recreational vehicle and is supported mainly by federal disability benefits, is doing well now, but continues to receive periodic chemotherapy to contain the cancer in his liver.
Like many people with a serious illness, Mr. Mannett got a quick education on navigating the financial straits of being treated for a major disease. He learned that smart medical consumers can save money if they track their bills as closely as they monitor their health.
Here’s some tips he learned:
• When his insurer disputed some doctors' bills, for instance, Mr. Mannett got both parties together on a conference call to work out a compromise.
• By getting acquainted with a case worker at his insurance company, he learned how to negotiate lower fees from surgeons before an operation took place.
• By becoming friendly with financial clerks at doctors' offices, he has been able to secure discounts on some services.
• Before writing any checks, he double-checked calculations on his insurer's explanations of benefits.
• He wrote letters asking for other charges to be waived because of "severe financial hardship."

Mr. Mannett estimates his efforts saved him more than $10,000 on the cost of the scans and lab exams.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap